Search - tctmd.com

Displaying 941 - 960 of 1188

Sort: Relevancy | Date

News Daily News

STREAM Substudy: Lytic Failure Means Worse Outcomes for Pharmacoinvasively Treated STEMI Patients

July 17, 2014

News Daily News

HEAT-PPCI发布：关于直接PCI中肝磷脂较比伐卢定有优势的差异性发现仍然难以理解

Yael L. Maxwell

July 17, 2014

News Daily News

HEAT-PPCI Published: Discrepant Finding of Heparin’s Superiority over Bivalirudin in Primary PCI Still Puzzles

Yael L. Maxwell

July 17, 2014

News Daily News

HEAT-PPCI Publicado: El Discrepante Hallazgo de la Superioridad de la Heparina sobre la Bivalirudina en PCI Primarias Sigue Confundiendo

Yael L. Maxwell

July 17, 2014

News Daily News

La Mortalidad a Largo Plazo es Peor en Pacientes NSTEMI de Raza Negra que en Pacientes de Raza Blanca con Discrepancias en el Tratamiento

July 17, 2014

Presentation

STREAM Substudy: Outcomes of Pharmacoinvasive Strategy for Successful vs Failed Fibrinolysis and Primary PCI in AMI

Presenter: R.C. Welsh

July 16, 2014

$Unfractionated Heparin vs Bivalirudin in Primary PCI: An Open-label, Single-Center, Randomized Trial$

Presentation

Unfractionated Heparin vs Bivalirudin in Primary PCI: An Open-label, Single-Center, Randomized Trial

Presenter: A. Shahzad

July 10, 2014

Presentation

Prasugrel vs Clopidogrel in STEMI Patients According to Timing of PCI

Presenter: J.A. Udell

June 17, 2014

News Daily News

Prasugrel Efficacy in STEMI Largely Unaffected by PCI Timing

Yael L. Maxwell

June 17, 2014

Presentation

Efficacy, Safety of Rivaroxaban vs Warfarin in Elderly Patients with Nonvalvular A-fib

Presenter: Jonathan L. Halperin

June 09, 2014

$Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial$

Presentation EuroPCR 2014

Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial

Presenter: Uwe Zeymer

May 21, 2014

News Conference News EuroPCR 2014

EUROMAX Subanalysis: Bivalirudin Bests Heparin Regardless of GPI Use in STEMI

Yael L. Maxwell

May 21, 2014

Presentation

Prasugrel plus Bivalirudin vs Clopidogrel plus Heparin in Patients with STEMI

Presenter: Stefanie Schulz

May 14, 2014

News Daily News

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

May 14, 2014

News Daily News

Bivalirudin Safer Than Heparin Alone in ‘Real-World’ PCI Patients Without STEMI

Yael L. Maxwell

May 01, 2014

Presentation

Ticagrelor vs Clopidogrel in Patients with NSTE-ACS With or Without Revascularization

Presenter: D. Lindholm

April 25, 2014

News Daily News

PLATO Substudy: Ticagrelor Reduces Mortality in NSTE-ACS Patients Regardless of Revascularization

L.A. McKeown

April 25, 2014

Presentation

Heparin Monotherapy or Bivalirudin During PCI in NSTE-ACS or Stable Ischemic Heart Disease

Presenter: Sripal Bangalore

April 22, 2014

Presentation

The Efficacy of Ticagrelor Is Maintained in Women with ACS Participating in the PLATO trial

Presenter: Steen Husted

April 16, 2014

News Daily News

PLATO Analysis: No Sex-Based Difference in Ticagrelor’s Safety and Efficacy

April 16, 2014

Advertisement

STREAM Substudy: Lytic Failure Means Worse Outcomes for Pharmacoinvasively Treated STEMI Patients

HEAT-PPCI发布：关于直接PCI中肝磷脂较比伐卢定有优势的差异性发现仍然难以理解

HEAT-PPCI Published: Discrepant Finding of Heparin’s Superiority over Bivalirudin in Primary PCI Still Puzzles

HEAT-PPCI Publicado: El Discrepante Hallazgo de la Superioridad de la Heparina sobre la Bivalirudina en PCI Primarias Sigue Confundiendo

La Mortalidad a Largo Plazo es Peor en Pacientes NSTEMI de Raza Negra que en Pacientes de Raza Blanca con Discrepancias en el Tratamiento

STREAM Substudy: Outcomes of Pharmacoinvasive Strategy for Successful vs Failed Fibrinolysis and Primary PCI in AMI

Unfractionated Heparin vs Bivalirudin in Primary PCI: An Open-label, Single-Center, Randomized Trial

Prasugrel vs Clopidogrel in STEMI Patients According to Timing of PCI

Prasugrel Efficacy in STEMI Largely Unaffected by PCI Timing

Efficacy, Safety of Rivaroxaban vs Warfarin in Elderly Patients with Nonvalvular A-fib

Routine bivalirudin is superior to unfractionated heparin + bailout GP IIb/IIIa inhibitors in patients with STEMI transported for primary PCI: A prespecified subgroup analysis of the EUROMAX trial

EUROMAX Subanalysis: Bivalirudin Bests Heparin Regardless of GPI Use in STEMI

Prasugrel plus Bivalirudin vs Clopidogrel plus Heparin in Patients with STEMI

BRAVE 4: Prasugrel Plus Bivalirudin Fails to Mitigate Stent Thrombosis in STEMI Patients

Bivalirudin Safer Than Heparin Alone in ‘Real-World’ PCI Patients Without STEMI

Ticagrelor vs Clopidogrel in Patients with NSTE-ACS With or Without Revascularization

PLATO Substudy: Ticagrelor Reduces Mortality in NSTE-ACS Patients Regardless of Revascularization

Heparin Monotherapy or Bivalirudin During PCI in NSTE-ACS or Stable Ischemic Heart Disease

The Efficacy of Ticagrelor Is Maintained in Women with ACS Participating in the PLATO trial

PLATO Analysis: No Sex-Based Difference in Ticagrelor’s Safety and Efficacy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content